Tag: astra
-
AstraZeneca taps gene pioneer Venter for huge drug-hunting sweep
By Ben Hirschler CAMBRIDGE, England (Reuters) – AstraZeneca, working with genome pioneer Craig Venter, is launching a massive gene hunt in the most comprehensive bet yet by a pharmaceutical firm on the potential of genetic variations to unlock routes to new medicines. The initiative, announced on Friday, involves sequencing up to 2 million human genomes…
-
UK agency backs cancer drug after Sanofi cuts price
LONDON (Reuters) – Britain's healthcare cost watchdog NICE said on Friday it had changed its mind and decided to recommend Sanofi's prostate cancer drug Jevtana after the French company agreed to a further discount. The National Institute for Health and Care Excellence (NICE) said the improved discount was “an excellent example of how pharma companies…
-
AstraZeneca buys most of Acerta for $4 billion to add cancer drug
By Ben Hirschler LONDON (Reuters) – AstraZeneca said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either…
-
AstraZeneca buys most of Acerta for $4 billion to add cancer drug
By Ben Hirschler LONDON (Reuters) – AstraZeneca said on Thursday it had agreed to buy 55 percent stake of privately held biotech firm Acerta Pharma for $4 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 billion paid either…
-
High schools listening to scientists, letting teens sleep
SEATTLE (AP) — More school districts around the U.S. are heeding the advice of scientists who have long said that expecting teens to show up to class before 8 a.m. isn't good for their health or their report cards.
-
AstraZeneca’s potential $3 billion cancer pill wins early approval
By Ben Hirschler LONDON (Reuters) – A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, won early U.S. approval on Friday, in a boost for the British drugmaker. Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales…